Polymer-protein and polymer-drug conjugates in cancer therapy

Current Opinion in Investigational Drugs

Volumn 4, Issue 6, 2003, Pages 701-709

  Thanou, Maya ^a   Duncan, Ruth ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

N (2 hydroxypropylmethacrylamide); PEGylation; Polyethyleneglycol (PEG); Polymer therapeutics; Tumor targeting

Indexed keywords

ALPHA FETOPROTEIN; AMINOELLIPTICINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AP 5280; ASPARAGINASE MACROGOL; ASPARAGINE; CARBAMIC ACID; CISPLATIN; CT 2106; CYTOTOXIC AGENT; FCE 28068; FCE 28069; FUMAGILLOL CHLOROACETYLCARBAMATE; GALACTOSAMINE; GELDANAMYCIN; GRANULOCYTE COLONY STIMULATING FACTOR; IODINATED POPPYSEED OIL; MACROGOL; MACROGOL CAMPTOTHECIN; MYELIN ASSOCIATED GLYCOPROTEIN CAMPTOTHECIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER GALACTOSE DOXORUBICIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER GLUCOSE DOXORUBICIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER PACLITAXEL; PACLITAXEL POLIGLUMEX; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PK 1; PK 2; PNU 166148; PNU 166945; POLYGLUTAMIC ACID CAMPTOTHECIN; POLYGLUTAMIC ACID PACLITAXEL; POLYMER PLATINATE; POLYMER PROTEIN CONJUGATE; PROTHECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN; ZINOSTATIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; BLADDER TOXICITY; BLOOD TOXICITY; BONE PAIN; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CELL LEVEL; CLINICAL TRIAL; COLORECTAL CANCER; DEPRESSION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOXICITY; DRUG URINE LEVEL; FATIGUE; HEPATITIS C; HUMAN; IMMUNOGENICITY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MOLECULAR WEIGHT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PERITONEUM CANCER; PLASMA HALF LIFE; PROTEIN STABILITY; RECURRENT CANCER; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; NEOPLASMS; POLYETHYLENE GLYCOLS; POLYMERS; PROTEINS;

EID: 0041664881     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Duncan R: The dawning era of polymer therapeutics. Nat Rev Drug Disc (2003) 2(5):347-360. A thorough review on the current status of polymer therapeutics.
2. Brocchini S, Duncan R: Pendent drugs, release from polymers. Encyclopedia of Controlled Drug Delivery. Mathiowitz E (Ed), John Wiley & Sons, NY, USA (1999):786-816.
3. Duncan R: Polymer-anticancer drug conjugates. In: Handbook of Anticancer Drug Development. Budman D, Calvert H, Rowinsky E (Eds), Lippincott Williams & Wilkins, Baltimore, MD, USA (2003) in press. Excellent review describing the current status of polymer-drug conjugates in clinical development and the issues of preclinical to clinical transfer.
4. Harris JM, Chess RB: Effect of pegylation on pharmaceuticals. Nat Rev Drug Disc (2003) 2(3):214-221.
5. Veronese FM, Harris JM: Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev (2002) 54(4):453-456. This issue is dedicated to the topic of PEG-protein conjugates and their therapeutic applications.
6. Maeda H, Matsumura Y: Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst (1989) 6(3):193-210. One of the initial reviews introducing the EPR theory as an explanation for the prolonged therapeutic effect of polymer-drug conjugates.
7. Kopecek J, Kopeckova P, Minko T, Lu Z: HPMA copolymer-anticancer drug conjugates: Design, activity and mechanism of action. Eur J Pharm Biopharm (2000) 50(1):61-81. Review describing the design and development of HPMA co-polymer conjugates.
8. Graham ML: PEG-aspargase: A review of clinical studies. Adv Drug Deliv Rev (2003): in press.
9. Kinstler O, Molineaux G, Treuheit M, Ladd D, Gegg C: Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev (2002) 54(4):477-485.
10. Reddy KR, Modi MW, Pedder S: Use of PEG-interferonα-2a (40KD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev (2002) 54(4):571-586.
11. Wang Y-S, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF: Structural and biological characterization of pegylated recombinant interferon α-2b and its therapeutic implications. Adv Drug Deliv Rev (2002) 54(4):547-570.
12. Veronese FM, Caliceti P, Schiavon O, Sergi M: Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev (2002) 54(4):587-606.
13. Satchi R, Connors TA, Duncan R: PDEPT: Polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br J Cancer (2001) 85(7):1070-1076.
14. Satchi-Fainaro R, Hailu H, Davies JW, Summerford C, Duncan R: PDEPT: Polymer directed enzyme prodrug therapy II. HPMA copolymer-β-lactamase and HPMA-C-Dox as a model combination. Bioconjug Chem (2003): in press.
15. Davis FF: The origin of pegnology. Adv Drug Deliv Rev (2002) 54(4):457-458. Commentary on pegylation from one of the pioneers in the field.
16. Roberts MJ, Bentley MD, Harris JM: Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev (2002) 54(4):459-476.
17. Chapman AP, Atoniw P, Spitali M, West S, Stephens S, King DJ: Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol (1999) 17(8):780-783.
18. Sato H: Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev (2002) 54(4):487-504.
19. Park YK, Abuchowski A, Davis S, Davis F: Pharmacology of Escherichia coli L-asparaginase polyethylene glycol adduct. Anticancer Res (1981) 1(6):373-376.
20. Mashburn LT, Wriston JC: Tumor inhibition effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys (1964) 105:450-452.
21. Ho DH, Brown NS, Yen A, Holmes R, Keating M, Abuchowski A, Newman RA, Krakoff IH: Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos (1986) 14(3):349-352.
22. Muss HB, Spell N, Scudiery D, Capizzi RL, Cooper MR, Cruz J, Jackson DV, Richards F II, Spurr CL, White DR et al: A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkin's lymphoma. Invest New Drugs (1990) 8(1):125-130.
23. Kurtzberg J, Moore JO, Scudiery D, Franklin A: A phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukemia. Proc Am Assoc Cancer Res (1988) 29:213.
24. Grebanier D, Chen A, Franklin A et al: Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy. Proc Am Assoc Cancer Res (1993) 34:304.
25. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ: Comparative pharmacokinetic studies of three L-asparaginase preparations. J Clin Oncol (1993) 11(9):1780-1786.
26. Holmes FA, Jones SE, O'Shaughnessey J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M et al: Comparable efficacy and safety profiles of a once-per-cycle pegfilgrastim and daily injection filgastrim in chemotherapy-induced neutropenia: A multicentre dose-finding study in women with breast cancer. Ann Oncol (2002) 13(6):903-906.
27. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J et al: A randomised, double-blind placebo-controlled phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood (1997) 90(12):4710-4718.
28. Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, Tendler CL: Pegylated interferonα-2b treatment for patients with solid tumors: A phase I/II study. J Clin Oncol (2002) 20(18):3841-3849.
29. Maeda H, Konno T: Metamorphosis of neocarzinostatin to SMANCS: Chemistry, biology, pharmacology, and clinical effect of the first prototype anticancer polymer therapeutic. In: Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug. Maeda H, Edo K, Ishida N (Eds), Springer Verlag, Berlin, Germany (1997):227-267.
30. Maeda H: SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Deliv Rev (2001) 46(1-3):169-185.
31. Konno T, Maeda H: Targeting chemotherapy of hepatocellular carcinoma: Arterial administration of SMANCS/lipiodol. In: Neoplasms of the Liver. Okada K, Ishak KG (Eds), Springer-Verlag, New York, NY, USA (1987):343-352.
32. Ringsdorf H: Structure and properties of pharmacologically active polymers. J Polymer Sci Polymer Symposium (1975) 51:135-153. Landmark publication introducing the concept of polymer-drug conjugates as therapeutics.
33. Ducan R: Drug-polymer conjugates: Potential for improved chemotherapy. Anticancer Drugs (1992) 3(3):175-210.
34. Matsumura Y, Maeda H: A new concept for macromolecular therapies in cancer chemotherapy: Mechanism of tumouritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res (1986) 46(12 Pt 1):6387-6292.
35. Duncan R, Cable HC, Lloyd JB, Rejmanaova P, Kopecek J: Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side chains in poly [N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Macromol Chem (1984) 184:1997-2008. This publication presents the smart design of enzymatically (cathepsin B) cleavable bonds between polymer and drug.
36. Shaffer SA, Lee CB, Nudelman E, Kumar A, Coon M, Stone I, De Vries P, Singer JW: Metabolism of poly-L-glutamic acid (PG) paclitaxel (CT-2103); Proteolysis by lysosomal cathepsin B and identification of intermediate metabolites. Proc Am Assoc Cancer Res (2002) 43:Abs 2067.
37. Vasey PA, Kaye SB, Morrison, R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S et al: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - Drug-polymer conjugates. Clin Cancer Res (1999) 5(1):83-94. First phase I trial describing synthetic-polymer anticancer conjugate.
38. Cassidy J: PK1: Results of phase I studies. Proc 4th Int Symp Polymer Ther: Form Laboratory to Clinical Practice, Cardiff, UK (2000):20.
39. Duncan R, Seymour LC, Scarlett L, Lloyd JB, Rejmanova P, Kopecek J: Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendant galactosamine residues after intravenous administration to rats. Biochem Biophy Acta (1986) 880(1):62-71. This paper describes an HPMA co-polymer-doxorubicin conjugate with pendant galactosamine demonstrating significant hepatocyte targeting.
40. Seymour LW, Ulbrich K, Wedge SR, Hume IC, Strohalm J, Duncan R: N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: Pharmacokinetics in DBA2 mice. Br J Cancer (1991) 63(6):859-866.
41. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ et al: Hepatic drug targeting: Phase I evaluation of polymer bound doxorubicin. J Cliin Oncol (2002) 20(6):1668-1676.
42. Meerum Terwogt JM, Ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH: Phase I cliical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs (2001) 12(4):315-323.
43. Schoemaker NE, Van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Grazia Porro M et al: A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer (2002) 87(6):608-614.
44. Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilso G, Duncan R: HPMA copolymer platinates as novel antitutmor agents: In vitro properties, pharmacokinetics and antitumor activity in vivo. Eur J Cancer (1999) 35(6):994-1002.
45. Gianasi E, Buckley RG, Latigo J, Wasil M, Duncan R: HPMA copolymers platinates containing dicarboxylato ligands. Preparations, characterisation and in vitro and in vivo evaluation. J Drug Targeting (2002) 10(7):549-556.
46. Li C, Yu DF, Newma RA, Cabral F, Stephens LC, Hunter N, Milas L, Wallace S: Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res (1998) 58(11):2404-2409. The first polymer conjugate based on the biodegradable carrier poly(L-glutamic acid) to later progress into clinical testing.
47. Li C, Price JE, Milas L, Hunter NR, Ke S, Yu DF, Charnsangevej C, Wallace S: Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res (1999) 5(4):891-897.
48. Li C, Ke S, Wu QP, Tansey W, Hunter N, Buchmiller LM, Milas L, Charnsagavej C, Wallace S: Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res (2001) 6(7):2829-2834.
49. Garfield D: New form of paclitaxel shows promise. Lancet Oncol (2001) 2:192.
50. Garzone PD, Mitchell P, Bolton MG, Nemunaitis J: Preliminary report of a phase I study of combination chemotherapy using CT-2103 and carboplatin in patients with solid tumors. Proc Am Soc Clin Oncol (2002) 21(2 Pt 2):Abs 2161.
51. Kudelka AP, Verschraegen CF, Loyer E, Wallace S, Gershenson DM, Hon J, Ho L, Garzone PD, Warner M, Bolton MG, Kavanagh JJ: Preliminary report of a phase I study of escalating dose PG-paclitaxel (CT-2103) and fixed dose cisplatin in patients with solid tumors. Proc Am Soc Clin Oncol (2002) 21(2 Pt 2):Abs 2146.
52. Schulz J, Burris HA, Redfern C, Mitchell P, Warner M, Bolton MG: Phase II study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-containing regimen. Proc Am Soc Clin Oncol (2002) 21(2 Pt 2):Abs 2330
53. Sabbatini P, Brown J, Aghajanian C, Hensley ML, Pezzulli S, Flaherty C, Lovegren M, Funt S, Warner M, Mitchell P, Bolton MG et al: A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer. Proc Am Soc Clin Oncol (2002) 21(1 Pt 2):Abs 871.
54. Harper H, Marsland T, Mitchell P, Infortuno J, Bolton MG: Phase II study of first line chemotherapy using CT-2103 in patients with non-small cell lung cnacer who are ≥ 70 years of age or who have PS = 2. Proc Am Soc Clin Oncol (2002) 21 (2 Pt 2):Abs 2685.
55. De Vries P, Bhatt R, Stone I, Klein P, Singer J: Optimisation of CT2106: A water soluble poly L-glutamic acid (PG)-camptothecin conjugate with enhanced in vivo antitumor efficacy. Proc AACR-NCI-EORC Int Conf (2001):Abs 100
56. Greenwald RB, Choe YH, McGuire J, Conover CD: Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev (2003) 55(2):217-250.
57. Ochoa L, Tolcher AW, Rizzo J, Schwartz GH, Patnaik A, Hammond L, McCreery H, Denis L, Hidalgo M, Kwiatek J, McGuire J et al: A phase I study of PEG-camptothecin (PEG-CPT) in patients with advanced solid tumors: A novel formulation for an insoluble but active agent. Proc Am Soc Clin Oncol (2000) 19:Abs 770.
58. Satchi-Fainaro R, Mamluk R, Puder M, Greene AK, Soker S, Folkman J: Polymer therapeutics of angiogenesis inhibitors: HPMA copolymer-TNP-470 conjugate. Proc Int Symp Controlled Release Bioactive Materials (2002) 29:209.
59. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, Duncan R: Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer (1995) 31A:766-770. The HPMA co-polymers with prolonged plasma circulation times (ie, MW > 40 KDa) demonstrated an MW-dependent accumulation in Sarconma 180 and B16F10 melanoma models, up to an MW of ∼ 750 KDa.
60. Tomlison R, Heller J, Duncan R, Brocchini S: Pendent chain functionalised polyacetals that display pH-dependent degradation: A platform for the development of novel polymer therapeutics. Macromolecules (2002) 35:473-480.
61. Hreczuk-Hirst D, Chicco D, German L, Duncan R: Dextrins as potential carriers for drug targeting: Tailored rates of dextrin degradation by introduction of pendant groups. Int J Pharm (2001) 230(1-2):57-66.
62. Malik N, Evagorou EG, Duncan R: Dendrimer-platinate: A novel approach to cancer chemotherapy. Anticancer Drugs (1999) 10(8):767-776.
63. Barth RF, Yang W, Adams DM, Rotaru JH, Shukla S, Sekido M, Tjarks W, Fenstermaker RA, Ciesielski M, Nawrocky MM, Coderre JA: Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res (2002) 62(11):3159-3166.
64. Duncan R, Gac-Breton S, Keane R, Musila R, Sat YN, Satchi R, Searle F: Polymer-drug conjugates, PDEPT and PELT: Basic principles for design and transfer from the laboratory to the clinic. J Control Release (2001) 74(1-3):135-146.
65. Searle F, Gac-Breton S, Keane R, Dimitrijevic S, Brocchini S, Sausville EA, Duncan R: N-(2-hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis in vitro and preliminary in vivo evaluation. Bioconjug Chem (2001) 12(5):711-718.
66. Kasuya Y, Lu ZR, Kopeckova P, Tabibi SE, Kopecek J: Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates. Pharm Res (2002) 19(2):115-123.
67. Varticovski L, Lu ZR, Mitchell K, De Aos I, Kopecek J: Water-soluble HPMA copolymer-wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo. J Control Release (2001) 74(1-3):275-281.
68. Allen TM: Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer (2002) 2(10):750-763.
69. Atkins JH, Gershell LJ: Selective anticancer drugs. Nat Rev Drug Disc (2002) 1(7):491-492.
70. Huang PS, Oliff A: Drug-targeting strategies in cancer therapy. Curr Opin Genet Dev (2001) 11(1):104-110.
71. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 2(10): 727-739.